

Consolidated Interim Financial Statements

June 30, 2020

DO NOT DISSEMINATE - The documents and information contained herein are confidential and protected pursuant to T.C.A. Section 68-11-272 and/or T.C.A. Section 68-11-238, as applicable, and are neither discoverable nor subject to production under Tennessee's Public Records Act or otherwise.

Table of Contents

Executive Summary	1
Consolidated Balance Sheet	2
Consolidated Statement of Operations	3
YTD Actual	4
YTD Budget	5
Statement of Cash Flows	6
Erlanger Statistical Volumes	7
Surgeries (Graph)	9
Bledsoe Statistical Volumes	10
Erlanger Western Carolina Statistical Volumes	11
Ratio Analysis	12
Notes to Combined Financial Statements	14

Erlanger Health System Executive Summary for the Year Ended June 30, 2020

The following financial information represents consolidated information for the Erlanger Health System, which includes:

Erlanger Medical Center(EMC) ContinuCare(CUC) Bledsoe (BLEDSOE) Health Centers(SSDA) HMO Trust (HMO) Erlanger Western Carolina(EWCH)

EMC Key Financial Indicators

- Net income from operations for Erlanger Health System for the year was \$35,270,824 compared to budgeted income of \$13,186,068 and
 prior year loss of \$3,995,307. For discussion purposes, the HHS stimulus funds are presented as operating income in accordance with FASB
 guidelines, as well as how most non-governmental hospitals in the industry are reporting. The discussion is for industry comparative purposes,
 accurate benchmarking and investor clarification. GASB requires HHS stimulus funds to be reported as non-operating revenue for audit
 purposes due to governmental status.
- Total net income for Erlanger Health System for the year was \$30,194,077 compared to budgeted income of \$5,000,000 and prior year loss
 of \$4,422,878.
- Admissions were 7.9% less than prior year and 13.0% under budget.
- Total cash reserves are \$305,902,397 (excluding \$111 million for Investment). Current accounts payable is \$101,429,945 for Erlanger Health System. Days cash on hand calculation is 146 days.
- Net income before interest, taxes, depreciation and amortization (EBITDA) for the year was \$75,267,323 compared to budget of \$53,053,702 and prior year EBITDA of \$38,189,769.
- Net days in accounts receivable is 55 days.

Volumes

The COVID-19 pandemic was the major influencer on volumes for fiscal 2020. On March 23, elective procedures were halted due to a Tennessee state moratorium associated with the pandemic. This moratorium was lifted May 1. The reopening plan was executed on May 1 in a systematic approach to ensure patient safety and successful results. Overall results after the moratorium was lifted trended extremely positively, with admissions rebounding 33% at yearend compared to April. Inpatient surgeries rallied back strong at a 62% increase from April. For the month of June, Erlanger was at prior year levels. Finally, outpatient elective surgeries were impacted the most from the state moratorium. Erlanger was one of the first providers to re-open elective surgeries once the moratorium was lifted. The result was a resounding success with a 231% increase in outpatient surgeries over April. Outpatient surgeries in June not only exceeded prior year by 11.2%, but exceeded budget by 1.2%. For the fiscal year, surgical inpatient volume was 8.2% under prior year and 12.4% less than budget. Births were 2.1% more than prior year and 1.7% over budget. Consistent with national trends during the pandemic, emergency room visits were 8.5% less than prior year and 9.6% under budget.

Even through the pandemic, observation days remained 9.3% over budget and 13.9% over prior year. Cardiac cath lab patients were 17.6% less than prior year and 10.4% under budget. Physician visits were 4.3% more than prior year and 7.6% under budget. Erlanger quickly adopted the telehealth model to help offset expected declines in office visits due to COVID-19. For the month of June, physician office visits were 13.4% over budget and 14.9% over prior year.

Income Statement Comments

The pandemic had a significant impact on lost revenues for the period of March through June 2020. The lost net patient revenue is estimated to be in excess of \$93 million for the System. Net patient revenue was \$55.8 million less than prior year and \$107.7 million less than budget. Net patient revenue per adjusted admission was \$8,344 compared to budget of \$8,580. The decrease was due to the inpatient/outpatient mix of the patient population. This rate is expected to increase as the surgical admissions return to normalcy. The Medicare case mix index was 1.92 compared to budget of 1.90. Bad debt & charity care as a % of gross patient revenue was 9.32% compared to budget of 8.08%. Total Medicare utilization was 2.9% less than budget and 3.2% under prior year. Medicaid utilization was 3.8% under budget and 1.9% less than prior year. Even through the pandemic, Erlanger maintained strong commercial utilization with a 2.8% Increase over budget and prior year payer mix. Indigent/self-pay utilization was at 7.7% compared to a budget of 6.8% and prior year of 7.1%.

The System recognized \$55.9 million of stimulus funds as non-patient revenue in the current year to partially offset lost revenues and increased expenses during the pandemic. Note that the stimulus funds are shown as operating revenue in accordance with FASB and the hospital industry as a whole. GASB requires the stimulus funds to be reported as non-operating revenue for audit purposes due to Erlanger's governmental status.

Erlanger took immediate action in March regarding cost containment as the pandemic started impacting the region. Erlanger was one of the first providers in the nation to implement decisive operational tactics to offset the projected loss revenue impact. In addition to the management action plan that was implemented in November 2019, prior to the pandemic, these additional measures saved the organization an estimated \$47 million year over year for April – June. Even though the admissions dropped drastically, the cost per adjusted admission was only over budget by \$277 per adjusted admission as fixed costs were spread over fewer admissions. Erlanger was able to manage the productivity per adjusted occupied bed to be under budget. Paid FTEs per adjusted occupied bed were 4.72 compared to budget of 4.80. Case mix adjusted length of stay was 3.00 compared to budget of 2.87 (4.8% over budget) and prior year of 2.97. COVID-19 patients long lengths of stay negatively impacted the length of stay metric. Salary cost per hour was \$36.61 compared to a budget of \$35.52. Supplies and drugs per adjusted admission (adjusted for wage index & case mix) were \$1,815 compared to budget of \$1,790.

Balance Sheet Comments

The balance sheet continued to strengthen as liquidity tactics were put in place in an effort to preserve cash during the pandemic. Days in cash increased from 74 days in fiscal 2019 to 146 days by the end of fiscal 2020. The Medicare advance payments that are due back to CMS within one year were not recognized as revenue in fiscal 2020, and they equate to 35 days of cash. Erlanger has not made any draws on the \$64 million lines of credit. During the fiscal year, Erlanger funded \$25 million in capital improvements compared to \$59.1 million in the prior year. Capital expenditures were temporarily put on hold in March due to the pandemic uncertainty and will resume in the upcoming fiscal year at the appropriate time when volumes are normalized. Pension contributions totaled \$9.8 million based on the actuarial funding schedule. Erlanger retired \$8.5 million of long-term debt during the fiscal year and generated a debt service coverage ratio of 3.62 compared to the 1.10 bond covenant minimum requirement. Decrease in other receivables is primarily due to receipt of prior year outstanding Tenncare GME payments. Decrease in other assets is due to loan payments received of \$2.6 million related to Hutcheson Medical Center. The due to third party payers line represents any governmental settlements that are outstanding for fiscal years 2012-2020 and the Medicare advance payments. Accounts payable and accrued expenses decreased by \$16.8 million compared to June 30, 2019 balances. The post-retirement benefits line item reflects the new GASB pension changes. The reserve for other liabilities includes long term PTO and self-insured malpractice liability.

J. Britton Tabor, EVP and CFO/Treasurer

ERLANGER HEALTH SYSTEM Unaudited Consolidated Balance Sheets as of: June 30, 2020

ASSETS	2020	2019
UNRESTRICTED FUND		
CURRENT Cash and temporary investments	\$ 305,902,397	\$ 113,584,247
Patient accounts receivable	480,742,524	564,072,693
Less allowances for patient A/R Net patient accounts receivable	(359,573,245) 121,169,279	<u>(404,858,451)</u> <u>159,214,242</u>
Other receivables	33,700,650	35,134,533
Due from third party payors	3,335,546	8,363,831
Inventories Prepaid expenses	23,379,356 7,579,812	22,336,279 7,295,214
Total current assets	495,067,040	345,928,346
NET PROPERTY, PLANT, AND EQUIPMENT	299,530,224	314,049,964
OTHER ASSETS		
Assets whose use is limited	120,116,838	111,932,991
Other assets	2,061,933	9,114,057
Total other assets	122,178,771	121,047,048
DEFERRED OUTFLOWS OF RESOURCES	40 604 000	42.700.000
Deferred pension adjustments Deferred amounts from debt refunding	12,621,229 1,525,356	12,780,999 2,115,816
Total deferred outflows of resources	14,146,585	14,896,815
TOTAL	\$ 930,922,620	\$ 795,922,173
LIABILITIES		
LIABILITIES	2020	2019
UNRESTRICTED FUND	2020	2019
UNRESTRICTED FUND CURRENT		
UNRESTRICTED FUND CURRENT Current maturities of long term debt	\$ 13,043,446	\$ 5,644,324
UNRESTRICTED FUND CURRENT Current maturities of long term debt Accounts payable	\$ 13,043,446 112,675,336	\$ 5,644,324 129,504,980
UNRESTRICTED FUND CURRENT Current maturities of long term debt	\$ 13,043,446	\$ 5,644,324
UNRESTRICTED FUND CURRENT Current maturities of long term debt Accounts payable Accrued salaries & related liabilities Deferred revenue Due to third party payors	\$ 13,043,446 112,675,336 46,084,485 18,466,088 113,475,563	\$ 5,644,324 129,504,980 41,815,568
UNRESTRICTED FUND CURRENT Current maturities of long term debt Accounts payable Accrued salaries & related liabilities Deferred revenue Due to third party payors Other current liabilities	\$ 13,043,446 112,675,336 46,084,485 18,466,088 113,475,563 4,755,905	\$ 5,644,324 129,504,980 41,815,568 2,284,840 - 1,888,118
UNRESTRICTED FUND CURRENT Current maturities of long term debt Accounts payable Accrued salaries & related liabilities Deferred revenue Due to third party payors	\$ 13,043,446 112,675,336 46,084,485 18,466,088 113,475,563	\$ 5,644,324 129,504,980 41,815,568 2,284,840
UNRESTRICTED FUND CURRENT Current maturities of long term debt Accounts payable Accrued salaries & related liabilities Deferred revenue Due to third party payors Other current liabilities	\$ 13,043,446 112,675,336 46,084,485 18,466,088 113,475,563 4,755,905	\$ 5,644,324 129,504,980 41,815,568 2,284,840 - 1,888,118
UNRESTRICTED FUND CURRENT Current maturities of long term debt Accounts payable Accrued salaries & related liabilities Deferred revenue Due to third party payors Other current liabilities Total current liabilities	\$ 13,043,446 112,675,336 46,084,485 18,466,088 113,475,563 4,755,905 308,500,823	\$ 5,644,324 129,504,980 41,815,568 2,284,840 - 1,888,118 181,137,830
UNRESTRICTED FUND CURRENT Current maturities of long term debt Accounts payable Accrued salaries & related liabilities Deferred revenue Due to third party payors Other current liabilities Total current liabilities POST RETIREMENT BENEFITS (GASB 67/68)	\$ 13,043,446 112,675,336 46,084,485 18,466,088 113,475,563 4,755,905 308,500,823 83,496,325	\$ 5,644,324 129,504,980 41,815,568 2,284,840 - 1,888,118 181,137,830 79,787,400
UNRESTRICTED FUND CURRENT Current maturities of long term debt Accounts payable Accrued salaries & related liabilities Deferred revenue Due to third party payors Other current liabilities Total current liabilities POST RETIREMENT BENEFITS (GASB 67/68) RESERVE FOR OTHER LIABILITIES	\$ 13,043,446 112,675,336 46,084,485 18,466,088 113,475,563 4,755,905 308,500,823 83,496,325 33,518,041	\$ 5,644,324 129,504,980 41,815,568 2,284,840 - 1,888,118 181,137,830 79,787,400 44,129,431
UNRESTRICTED FUND CURRENT Current maturities of long term debt Accounts payable Accrued salaries & related liabilities Deferred revenue Due to third party payors Other current liabilities Total current liabilities POST RETIREMENT BENEFITS (GASB 67/68) RESERVE FOR OTHER LIABILITIES DEFERRED GAIN FROM SALE-LEASEBACK	\$ 13,043,446 112,675,336 46,084,485 18,466,088 113,475,563 4,755,905 308,500,823 83,496,325 33,518,041 1,485,052	\$ 5,644,324 129,504,980 41,815,568 2,284,840 - 1,888,118 181,137,830 79,787,400 44,129,431 1,881,397
UNRESTRICTED FUND CURRENT Current maturities of long term debt Accounts payable Accrued salaries & related liabilities Deferred revenue Due to third party payors Other current liabilities Total current liabilities POST RETIREMENT BENEFITS (GASB 67/68) RESERVE FOR OTHER LIABILITIES DEFERRED GAIN FROM SALE-LEASEBACK LONG - TERM DEBT FUND BALANCE Unrestricted	\$ 13,043,446 112,675,336 46,084,485 18,466,088 113,475,563 4,755,905 308,500,823 83,496,325 33,518,041 1,485,052 187,839,024 213,862,035	\$ 5,644,324 129,504,980 41,815,568 2,284,840 - 1,888,118 181,137,830 79,787,400 44,129,431 1,881,397 203,037,271
UNRESTRICTED FUND CURRENT Current maturities of long term debt Accounts payable Accrued salaries & related liabilities Deferred revenue Due to third party payors Other current liabilities Total current liabilities POST RETIREMENT BENEFITS (GASB 67/68) RESERVE FOR OTHER LIABILITIES DEFERRED GAIN FROM SALE-LEASEBACK LONG - TERM DEBT FUND BALANCE Unrestricted Invested in capital assets, net of related debt	\$ 13,043,446 112,675,336 46,084,485 18,466,088 113,475,563 4,755,905 308,500,823 83,496,325 33,518,041 1,485,052 187,839,024 213,862,035 98,649,976	\$ 5,644,324 129,504,980 41,815,568 2,284,840 - 1,888,118 181,137,830 79,787,400 44,129,431 1,881,397 203,037,271 175,057,639 105,372,484
UNRESTRICTED FUND CURRENT Current maturities of long term debt Accounts payable Accrued salaries & related liabilities Deferred revenue Due to third party payors Other current liabilities Total current liabilities POST RETIREMENT BENEFITS (GASB 67/68) RESERVE FOR OTHER LIABILITIES DEFERRED GAIN FROM SALE-LEASEBACK LONG - TERM DEBT FUND BALANCE Unrestricted Invested in capital assets, net of related debt Restricted	\$ 13,043,446 112,675,336 46,084,485 18,466,088 113,475,563 4,755,905 308,500,823 83,496,325 33,518,041 1,485,052 187,839,024 213,862,035 98,649,976 3,571,344	\$ 5,644,324 129,504,980 41,815,568 2,284,840 - 1,888,118 181,137,830 79,787,400 44,129,431 1,881,397 203,037,271 175,057,639 105,372,484 5,518,721
UNRESTRICTED FUND CURRENT Current maturities of long term debt Accounts payable Accrued salaries & related liabilities Deferred revenue Due to third party payors Other current liabilities Total current liabilities POST RETIREMENT BENEFITS (GASB 67/68) RESERVE FOR OTHER LIABILITIES DEFERRED GAIN FROM SALE-LEASEBACK LONG - TERM DEBT FUND BALANCE Unrestricted Invested in capital assets, net of related debt	\$ 13,043,446 112,675,336 46,084,485 18,466,088 113,475,563 4,755,905 308,500,823 83,496,325 33,518,041 1,485,052 187,839,024 213,862,035 98,649,976	\$ 5,644,324 129,504,980 41,815,568 2,284,840 - 1,888,118 181,137,830 79,787,400 44,129,431 1,881,397 203,037,271 175,057,639 105,372,484

Erlanger Health System Unaudited Consolidated Statement of Operations For the periods ended June 30, 2020 and 2019

	L		Vear to Date		
		Actual	Budget	Prior	Prior Year
OPERATING REVENUE Net patient service revenue Other revenue	\$	993,621,422 \$ 82,268,225	1,101,320,601 27,581,940	\$ 1,04 2	1,049,466,244 24,470,400
Total operating revenue	1,	1,075,889,647	1,128,902,541	1,07	1,073,936,644
OPERATING EXPENSES		576 535 51E	624 GEO 88E	O Y	504 160 446
Supplies		146,368,400	157,118,895	15	156,527,193
Purchased services		208,540,778	219,728,393	21	211,463,572
Utilities		10,900,379	9,915,235	_	11,776,906
Drugs		53,666,100	61,804,324	9	61,225,761
Depreciation		39,234,455	39,485,261	ñ	38,512,823
Insurance & taxes	\	5,373,196	6,003,480	. 10.4	4,265,250
i otal operating expenses	_	,040,016,623	1,113,710,473	70,1	008,188,770,
Operating income (loss)		35,270,824	13,186,068		(3,995,307)
NONOPERATING REVENUE (EXPENSES)					
Gain (loss) on disposal of assets		470,640	(200,000)		3,625,258
Investment Income (loss), net of fees Interest expense		3,550,831 (9.094,998)	1,661,276		4,665,618 (8,722,585)
Provisions for income tax		(3,220)			4,138
Net income (loss)	₩	30,194,077 \$	5,000,000	\$	(4,422,878)
EBITDA		75,267,323	53,053,702	ñ	38,189,769
Operating Margin		3.28%	1.17%		-0.37%
Total Margin		2.81%	0.44%		-0.41%
Salaries/benefits as % of total operating revenue		53.59%	55.07%		55.33%

Erlanger Health System Unaudited Consolidated Statement of Operations For the period ended June 30, 2020

YTD ACTUAL

				Primary Health System	Ith System				EHS
		EMC	BLEDSOE	HMO TRUST	SŠDA	EWCH	Total	cnc	Total
PATIENT SERVICE REVENUE									
Inpatient services	↔	1,888,315,685	7,833,296		898,510	29,295,477	1,926,342,968	ı	1,926,342,968
Outpatient services	ļ	1,662,904,290	63,902,384		8,969,024	139,257,446	1,875,033,144	6,223	1,875,039,367
Total patient service revenue		3,551,219,975	71,735,680	-	9,867,534	168,552,923	3,801,376,112	6,223	3,801,382,335
LESS: REVENUE DEDUCTIONS									
Certified free care		6,191,997	3,296	,			6,195,293		6,195,293
Charity care		250,025,311	6,400,843	٠		6,900,529	263,326,683		263,326,683
Bad debt expense		74,595,126	1,882,642	•		9,551,085	86,028,853		86,028,853
Medicare and medicaid rate adjustments		992,682,380	25,586,392		(2,188,296)	81,117,138	1,097,197,614		1,097,197,614
Contractual adjustments and policy discounts		1,305,886,487	24,445,374	-	6,396,321	18,284,288	1,355,012,470	•	1,355,012,470
Total revenue deductions		2,629,381,301	58,318,547	-	4,208,025	115,853,040	2,807,760,913	1	2,807,760,913
Net patient service revenue		921,838,674	13,417,133	•	5,659,509	52,699,883	993,615,199	6,223	993,621,422
Nonpatient service revenue Investment in joint ventures		65,520,660 (419,827)	4,658,920		3,404,681	9,061,128	82,645,389 (419,827)	3,480 39,183	82,648,869 (380,644)
Total operating revenue	J	986,939,507	18,076,053	1	9,064,190	61,761,011	1,075,840,761	48,886	1,075,889,647
OPERATING EXPENSES									
Salaries and employee benefits		531,818,115	8,046,427	ı	5,575,900	31,093,429	576,533,871	1,644	576,535,515
Supplies		140,551,326	712,809	•	192,951	4,910,977	146,368,063	337	146,368,400
Purchased services		193,440,905	2,504,201	•	1,195,165	11,032,145	208,172,416	368,362	208,540,778
Utilities		9,476,715	258,527		116,642	1,046,936	10,898,820	1,559	10,900,379
Drugs		49,125,941	340,061		(298,177)	4,498,275	53,666,100		53,666,100
Depreciation		38,396,303	143,646	•	170,442	524,064	39,234,455		39,234,455
Insurance & taxes		4,920,733	11,294	•	25,643	415,526	5,373,196		5,373,196
Corporate overhead allocation	ļ	(11,566,272)	2,727,384		800,004	8,038,884	•	·	
Total operating expenses	J	956,163,766	14,744,349	•	7,778,570	61,560,236	1,040,246,921	371,902	1,040,618,823
Operating income (loss)		30,775,741	3,331,704	ı	1,285,620	200,775	35,593,840	(323,016)	35,270,824
NONOPERATING REVENUE (EXPENSES)									
Gain (loss) on disposal of assets		342,574	1		(9,372)	137,438	470,640	1	470,640
Investment income (loss), net of fees		3,700,178	(124)	45,317	(1,235)	153,518	3,897,654	(346,823)	3,550,831
Interest expense Provisions for income tax		(9,092,869)				(2,129)	(9,094,998)	(3,220)	(9,094,998) (3,220)
Net income (loss)	↔	25,725,624	3,331,580	45,317	1,275,013	489,602	30,867,136	(673,059)	30,194,077

Erlanger Health System Unaudited Consolidated Statement of Operations For the period ended June 30, 2020

	Ĺ				YTD	YTD BUDGET			
			f	Primary Health System	Ilth System				EHS
PATIENT SERVICE REVENUE		EMC	BLEDSOE	HMO TRUST	SSDA	EWCH	Total	cnc	Total
Inpatient services Outpatient services	↔	2,077,325,122 1,777,924,449	9,567,786 65,984,858		360,824 10,553,433	36,135,088 151,832,401	2,123,388,820 2,006,295,141	10,584	2,123,388,820 2,006,305,725
Total patient service revenue		3,855,249,571	75,552,644		10,914,257	187,967,489	4,129,683,961	10,584	4,129,694,545
LESS: REVENUE DEDUCTIONS									
Certified free care		9,244,810	•				9,244,810		9,244,810
Charity care		177,153,923	5,219,046	1	,	8,074,558	190,447,527	•	190,447,527
Bad debt expense		125,082,704	3,244,499	•		10,747,358	139,074,561	•	139,074,561
Medicare and medicaid rate adjustments Contractual adjustments and policy discounts		1,120,652,700	28,715,178		- 4 873 001	89,709,386	1,239,077,264		1,239,077,264
Total revenue deductions		2,836,029,354	61,051,545		4,873,001	126,420,044	3,028,373,944		3,028,373,944
Net patient service revenue		1,019,220,217	14,501,099	•	6,041,256	61,547,445	1,101,310,017	10,584	1,101,320,601
Nonpatient service revenue Investment in joint ventures	l	20,599,288 230,514	741,500		3,122,003	2,888,635	27,351,426 230,514		27,351,426 230,514
Total operating revenue	ļ	1,040,050,019	15,242,599	1	9,163,259	64,436,080	1,128,891,957	10,584	1,128,902,541
OPERATING EXPENSES									
Salaries and employee benefits		574,438,849	8,246,197	1	6,636,830	32,332,409	621,654,285	009'9	621,660,885
Supplies		149,880,859	755,522		218,214	6,264,300	157,118,895	- 700	157,118,895
Purchased services		203,688,093	3,152,365		1,401,548	11,281,567	219,523,573	204,820	219,728,393
		0,202,007	402,500		157,590	1,241,332	9,915,255		9,915,235
Drugs		30,011,106	492,516		(255,426)	4,000,120	20 405 264		01,604,324
Depreciation		5 581 844	34 805		73.365	439,204 333 226	59,465,261 6,003,240	240	59,463,261
Corporate overhead allocation		(11,522,283)	2,683,395	-	800,000	8,038,888)	, , , , ,
Total operating expenses	l	1,026,111,560	15,742,682	•	9,163,259	64,487,312	1,115,504,813	211,660	1,115,716,473
Operating income (loss)		13,938,459	(500,083)			(51,232)	13,387,144	(201,076)	13,186,068
NONOPERATING REVENUE (EXPENSES)									
Gain (loss) on disposal of assets		(200,000)	,	' 0	1	- 1000	(200,000)		(200,000)
investment income (loss), net of rees Interest expense		(9,644,386)	8 ,	000,		320,730 (2,958)	(9,647,344)		(9,647,344)
Provisions for income tax	I								
Net income (loss)	₩	5,169,556	(200,000)	1,000		266,560	4,937,116	62,884	5,000,000

Erlanger Health System Statement of Cash Flows For the period ended June 30, 2020


Income from operations \$ 35,270,824 Adjustments to reconcile operating loss to net cash provided by operating activities: Depreciation and amortization \$ 39,234,455 Provision for self-insurance \$ (3,081,571) Gain on disposal of assets \$ (470,640) Changes in assets and liabilities: Net patient accounts receivable \$ 38,044,963 Due to third party payers \$ 118,503,848 Inventory and other current assets \$ 7,265,989 Other assets \$ (197,876) Accounts payable and accrued expenses \$ (16,829,644) Accrued salaries and related liabilities \$ 4,268,917 Deferred revenue \$ 16,181,248 Other current liabilities and long-term liabilities \$ (4,893,733) Net cash provided by operating activities \$ (24,714,715) Proceeds from sale of assets \$ (24,714,715) Proceeds from sale of assets \$ (24,714,715) Proceeds from sale of assets \$ (24,714,715) Proceeds from issuance of long-term debt \$ (8,805,030) Contributions for capital assets \$ (8,288,038) Proceeds from issuance of long-term debt \$ (8,805,030) Contributions for capital assets \$ (8,288,038) Proceeds from issuance of long-term debt \$ (8,805,030) Contributions for capital assets \$ (8,288,038) Proceeds from issuance of long-term debt \$ (8,805,030) Contributions for capital assets \$ (8,288,038) Proceeds from issuance of long-term debt \$ (8,805,030) Contributions for capital assets \$ (8,288,038) Proceeds from issuance of long-term debt \$ (8,805,030) Contributions for capital assets \$ (8,288,038) Proceeds from issuance of long-term debt \$ (8,805,030) Contributions for capital assets \$ (8,288,038) Proceeds from issuance of long-term debt \$ (8,805,030) Contributions for capital assets \$ (8,288,038) Proceeds from issuance of long-term debt \$ (8,805,030) Contributions for capital assets \$ (8,288,038) Proceeds from issuance of long-term debt \$ (8,1805,030) Contributions for capital assets \$ (8,288,038) Proceeds from issuance of long-term debt \$ (8,288,038) Proceeds from issuance of long-term debt \$ (8,288,038) Proceeds from issuance of long-term debt \$ (8,288,038) Proceeds from issuance of lo	Operating activities		
provided by operating activities: Depreciation and amortization Provision for self-insurance Gain on disposal of assets Changes in assets and liabilities: Net patient accounts receivable Due to third party payers Inventory and other current assets Other assets Inventory and other current assets Other assets Inventory and excrued expenses Other current liabilities Accounts payable and accrued expenses Inventory and related liabilities Accounts payable and long-term liabilities Other current liabilities and long-term liabilities Other current liabilities and long-term liabilities Acquisition and construction of capital assets Acquisition and construction of capital assets Proceeds from sale of assets Principal paid on bonds payable and capital lease obligations Proceeds from issuance of long-term debt Interest payments on long-term debt Other capital assets Ret cash used in capital and related financing activities Investing activities Investing activities Investing activities Investment income Payment received on note receivable Net cash transferred to assets limited as to use Net cash used in investing activities Increase in cash and cash equivalents	Income from operations	\$	35,270,824
Depreciation and amortization Provision for self-insurance Gain on disposal of assets (470,640) Changes in assets and liabilities: Net patient accounts receivable Due to third party payers Investing activities Other assets Acquisition and construction of capital and related financing activities Proceeds from issuance of long-term debt Net cash used in investing activities Investment income Payment received on note receivable Net cash and cash equivalents Other cash and cash equivalents Other current liabilities and long-term liabilities Acquisition and construction of capital assets Proceeds from sale of assets Net cash and cash equivalents Other current liabilities Acquisition and construction of capital assets Proceeds from sale of assets Acquisition and construction of capital assets Proceeds from issuance of long-term debt Acquisition and construction of capital assets Proceeds from issuance of long-term debt Acquisition and construction of capital lease obligations Acquisition and construction of capital assets Acquisition and construction of capital lease obligations Acquisition and construction of capital assets Acquisition and related financing activities Acquisition and construction of capital assets Acquisition and construction of capital assets Acquisition and related financing activities Acquisition and construction of capital assets Acquisition and construction of capital assets Acquisition and construction of capital assets Acquisition and construction of	Adjustments to reconcile operating loss to net cash		
Provision for self-insurance (3,081,571) Gain on disposal of assets (470,640) Changes in assets and liabilities: Net patient accounts receivable 38,044,963 Due to third party payers 118,503,848 Inventory and other current assets 7,265,989 Other assets (197,876) Accounts payable and accrued expenses (16,829,644) Accrued salaries and related liabilities 4,268,917 Deferred revenue 16,181,248 Other current liabilities and long-term liabilities (4,893,733) Net cash provided by operating activities 233,296,780 Capital and related financing activities Acquisition and construction of capital assets (24,714,715) Proceeds from sale of assets 369,121 Principal paid on bonds payable and capital lease obligations (8,288,038) Proceeds from issuance of long-term debt 740,000 Interest payments on long-term debt (8,805,030) Contributions for capital assets 893,352 Net cash used in capital and related financing activities (39,805,310) Investing activities Investment income 1,371,806 Payment received on note receivable 2,600,000 Net cash transferred to assets limited as to use (5,145,126) Net cash used in investing activities 192,318,150 Cash and cash equivalents, beginning of period 113,584,247	provided by operating activities:		
Gain on disposal of assets Changes in assets and liabilities: Net patient accounts receivable Due to third party payers Inspect of third party payers Other assets Other assets Accounts payable and accrued expenses Accrued salaries and related liabilities Deferred revenue Other current liabilities and long-term liabilities Other current liabilities and long-term liabilities Net cash provided by operating activities Capital and related financing activities Acquisition and construction of capital assets Proceeds from sale of assets Proceeds from issuance of long-term debt Principal paid on bonds payable and capital lease obligations Proceeds from issuance of long-term debt Other cash used in capital and related financing activities 1369,121 Principal paid on bonds payable and capital lease obligations Proceeds from issuance of long-term debt Rayments on long-term debt Rayment received on note receivable Royment received on note receivable Net cash used in investing activities Investment income Payment received on note receivable Net cash used in investing activities Increase in cash and cash equivalents Saya, 318, 150 Cash and cash equivalents, beginning of period	Depreciation and amortization		39,234,455
Changes in assets and liabilities: Net patient accounts receivable Due to third party payers Il18,503,848 Inventory and other current assets Other assets (197,876) Accounts payable and accrued expenses Accrued salaries and related liabilities Accrued salaries and related liabilities Other current liabilities and long-term liabilities Other current liabilities and long-term liabilities Acquisition and construction of capital assets Acquisition and construction of capital assets Proceeds from sale of assets Principal paid on bonds payable and capital lease obligations Proceeds from issuance of long-term debt Ontributions for capital assets Net cash used in capital and related financing activities Investing activities Investing activities Investment income Payment received on note receivable Net cash used in investing activities Net cash used in investing activities Increase in cash and cash equivalents Cash and cash equivalents, beginning of period 113,584,247	Provision for self-insurance		(3,081,571)
Net patient accounts receivable38,044,963Due to third party payers118,503,848Inventory and other current assets7,265,989Other assets(197,876)Accounts payable and accrued expenses(16,829,644)Accrued salaries and related liabilities4,268,917Deferred revenue16,181,248Other current liabilities and long-term liabilities(4,893,733)Net cash provided by operating activities233,296,780Capital and related financing activitiesAcquisition and construction of capital assets(24,714,715)Proceeds from sale of assets369,121Principal paid on bonds payable and capital lease obligations(8,288,038)Proceeds from issuance of long-term debt740,000Interest payments on long-term debt(8,805,030)Contributions for capital assets893,352Net cash used in capital and related financing activities(39,805,310)Investing activitiesInvesting activities2,600,000Net cash used in investing activities(5,145,126)Net cash used in investing activities(1,173,320)Increase in cash and cash equivalents192,318,150Cash and cash equivalents, beginning of period113,584,247	Gain on disposal of assets		(470,640)
Due to third party payers Inventory and other current assets Other assets Other assets Other assets (197,876) Accounts payable and accrued expenses (16,829,644) Accrued salaries and related liabilities Accounts payable and accrued expenses Other current liabilities and long-term liabilities Other current liabilities and long-term liabilities (4,893,733) Net cash provided by operating activities Capital and related financing activities Acquisition and construction of capital assets Acquisition and construction of capital assets Proceeds from sale of assets Principal paid on bonds payable and capital lease obligations Proceeds from issuance of long-term debt Other capital assets Net cash used in capital and related financing activities Investing activities Investing activities Investment income Payment received on note receivable Net cash used in investing activities Net cash used in investing activities Increase in cash and cash equivalents Cash and cash equivalents, beginning of period 113,584,247	Changes in assets and liabilities:		
Inventory and other current assets Other assets (197,876) Accounts payable and accrued expenses (16,829,644) Accrued salaries and related liabilities Accounted revenue 16,181,248 Other current liabilities and long-term liabilities (4,893,733) Net cash provided by operating activities Capital and related financing activities Acquisition and construction of capital assets Acquisition and construction of capital assets Proceeds from sale of assets 369,121 Principal paid on bonds payable and capital lease obligations Proceeds from issuance of long-term debt Principal paid on bonds payable and capital lease obligations Proceeds from issuance of long-term debt (8,805,030) Contributions for capital assets Net cash used in capital and related financing activities Investing activities Investing activities Investment income Payment received on note receivable Net cash used in investing activities Increase in cash and cash equivalents Cash and cash equivalents, beginning of period 113,584,247	Net patient accounts receivable		38,044,963
Other assets (197,876) Accounts payable and accrued expenses (16,829,644) Accrued salaries and related liabilities 4,268,917 Deferred revenue 16,181,248 Other current liabilities and long-term liabilities (4,893,733) Net cash provided by operating activities 233,296,780 Capital and related financing activities Acquisition and construction of capital assets (24,714,715) Proceeds from sale of assets 369,121 Principal paid on bonds payable and capital lease obligations (8,288,038) Proceeds from issuance of long-term debt 740,000 Interest payments on long-term debt (8,805,030) Contributions for capital assets 893,352 Net cash used in capital and related financing activities (39,805,310) Investing activities Investment income 1,371,806 Payment received on note receivable 2,600,000 Net cash transferred to assets limited as to use (5,145,126) Net cash used in investing activities (1,173,320) Increase in cash and cash equivalents 192,318,150 Cash and cash equivalents, beginning of period 113,584,247	Due to third party payers		118,503,848
Accounts payable and accrued expenses Accrued salaries and related liabilities Accrued salaries and related liabilities Deferred revenue Other current liabilities and long-term liabilities (4,893,733) Net cash provided by operating activities Capital and related financing activities Acquisition and construction of capital assets Acquisition and construction of capital assets Proceeds from sale of assets Principal paid on bonds payable and capital lease obligations Proceeds from issuance of long-term debt Interest payments on long-term debt Contributions for capital assets Net cash used in capital and related financing activities Investing activities Investing activities Investment income Payment received on note receivable Net cash transferred to assets limited as to use (5,145,126) Net cash used in investing activities Increase in cash and cash equivalents Cash and cash equivalents, beginning of period (11,75,320)	Inventory and other current assets		7,265,989
Accrued salaries and related liabilities 4,268,917 Deferred revenue 16,181,248 Other current liabilities and long-term liabilities (4,893,733) Net cash provided by operating activities 233,296,780 Capital and related financing activities Acquisition and construction of capital assets (24,714,715) Proceeds from sale of assets 369,121 Principal paid on bonds payable and capital lease obligations (8,288,038) Proceeds from issuance of long-term debt 740,000 Interest payments on long-term debt (8,805,030) Contributions for capital assets 893,352 Net cash used in capital and related financing activities (39,805,310) Investing activities Investment income 1,371,806 Payment received on note receivable 2,600,000 Net cash transferred to assets limited as to use (5,145,126) Net cash used in investing activities (1,173,320) Increase in cash and cash equivalents 192,318,150 Cash and cash equivalents, beginning of period 113,584,247	Other assets		(197,876)
Deferred revenue Other current liabilities and long-term liabilities (4,893,733) Net cash provided by operating activities Capital and related financing activities Acquisition and construction of capital assets Proceeds from sale of assets Principal paid on bonds payable and capital lease obligations Proceeds from issuance of long-term debt Principal paid on bonds payable and capital lease obligations Proceeds from issuance of long-term debt Principal paid on bonds payable and capital lease obligations Proceeds from issuance of long-term debt Resolvable Interest payments on long-term debt Resolvable Resolv	Accounts payable and accrued expenses		(16,829,644)
Other current liabilities and long-term liabilities (4,893,733) Net cash provided by operating activities 233,296,780 Capital and related financing activities Acquisition and construction of capital assets (24,714,715) Proceeds from sale of assets 369,121 Principal paid on bonds payable and capital lease obligations (8,288,038) Proceeds from issuance of long-term debt 740,000 Interest payments on long-term debt (8,805,030) Contributions for capital assets 893,352 Net cash used in capital and related financing activities (39,805,310) Investing activities Investment income 1,371,806 Payment received on note receivable 2,600,000 Net cash transferred to assets limited as to use (5,145,126) Net cash used in investing activities (1,173,320) Increase in cash and cash equivalents 192,318,150 Cash and cash equivalents, beginning of period 113,584,247	Accrued salaries and related liabilities		4,268,917
Net cash provided by operating activities Capital and related financing activities Acquisition and construction of capital assets Proceeds from sale of assets Principal paid on bonds payable and capital lease obligations Proceeds from issuance of long-term debt Principal paid on bonds payable and capital lease obligations Proceeds from issuance of long-term debt Principal paid on bonds payable and capital lease obligations Proceeds from issuance of long-term debt Principal paid on bonds payable and capital lease obligations Proceeds from issuance of long-term debt Principal paid on bonds payable and capital lease obligations Proceeds from issuance of long-term debt Principal paid on bonds payable and capital lease obligations Proceeds from issuance of long-term debt Principal paid on bonds payable and capital lease obligations Proceeds from issuance of long-term debt Principal paid on bonds payable and capital lease obligations Proceeds from issuance of long-term debt Principal paid on bonds payable and capital lease obligations Proceeds from issuance of long-term debt Principal paid on bonds payable and capital lease obligations Proceeds from issuance of long-term debt Principal paid on bonds payable and capital lease obligations Proceeds from issuance of long-term debt Principal paid on bonds payable and capital lease obligations Proceeds from issuance of long-term debt Principal paid on bonds payable and capital lease obligations Proceeds from sale of 24,714,715) Principal paid on bonds payable and capital lease obligations Proceeds from sale of 24,714,715) Principal paid on bonds payable and capital lease obligations Proceeds from sale of 24,714,715) Principal paid on bonds payable and capital lease obligations Proceeds from sale of 24,714,715) Principal paid on bonds payable and capital lease obligations Proceeds from sale of 24,714,715) Principal paid on bonds payable and capital lease obligations Proceeds from sale of 24,714,715) Principal paid on bonds payable and capital lease obligations Proceeds fr	Deferred revenue		16,181,248
Capital and related financing activities Acquisition and construction of capital assets Proceeds from sale of assets Principal paid on bonds payable and capital lease obligations Proceeds from issuance of long-term debt Interest payments on long-term debt Contributions for capital assets Net cash used in capital and related financing activities Investing activities Investment income Payment received on note receivable Net cash used in investing activities Increase in cash and cash equivalents Cash and cash equivalents, beginning of period (24,714,715) (24,000 (24,714,715) (24,000)	Other current liabilities and long-term liabilities		(4,893,733)
Acquisition and construction of capital assets Proceeds from sale of assets 369,121 Principal paid on bonds payable and capital lease obligations Proceeds from issuance of long-term debt Interest payments on long-term debt (8,805,030) Contributions for capital assets Net cash used in capital and related financing activities Investing activities Investment income Payment received on note receivable Net cash transferred to assets limited as to use Net cash used in investing activities Increase in cash and cash equivalents Cash and cash equivalents, beginning of period (24,714,715) (8,288,038) (8,288,038) (1,2000) (8,805,030) (8,288,038) (1,800,000) (8,805,030) (1,933,352) (1,933,352) (1,937,806) (1,937,806) (1,173,320) (1,173,320)	Net cash provided by operating activities		233,296,780
Acquisition and construction of capital assets Proceeds from sale of assets 369,121 Principal paid on bonds payable and capital lease obligations Proceeds from issuance of long-term debt Interest payments on long-term debt (8,805,030) Contributions for capital assets Net cash used in capital and related financing activities Investing activities Investment income Payment received on note receivable Net cash transferred to assets limited as to use Net cash used in investing activities Increase in cash and cash equivalents Cash and cash equivalents, beginning of period (24,714,715) (8,288,038) (8,288,038) (1,2000) (8,805,030) (8,288,038) (1,800,000) (8,805,030) (1,933,352) (1,933,352) (1,937,806) (1,937,806) (1,173,320) (1,173,320)	Canital and related financing activities		
Proceeds from sale of assets Principal paid on bonds payable and capital lease obligations Proceeds from issuance of long-term debt Proceeds from issuanc			(24 744 745)
Principal paid on bonds payable and capital lease obligations Proceeds from issuance of long-term debt 740,000 Interest payments on long-term debt (8,805,030) Contributions for capital assets 893,352 Net cash used in capital and related financing activities (39,805,310) Investing activities Investment income 1,371,806 Payment received on note receivable 2,600,000 Net cash transferred to assets limited as to use (5,145,126) Net cash used in investing activities (1,173,320) Increase in cash and cash equivalents 192,318,150 Cash and cash equivalents, beginning of period 113,584,247	·		
Proceeds from issuance of long-term debt 740,000 Interest payments on long-term debt (8,805,030) Contributions for capital assets 893,352 Net cash used in capital and related financing activities (39,805,310) Investing activities Investment income 1,371,806 Payment received on note receivable 2,600,000 Net cash transferred to assets limited as to use (5,145,126) Net cash used in investing activities (1,173,320) Increase in cash and cash equivalents 192,318,150 Cash and cash equivalents, beginning of period 113,584,247			
Interest payments on long-term debt Contributions for capital assets Net cash used in capital and related financing activities Investing activities Investment income Payment received on note receivable Net cash transferred to assets limited as to use Net cash used in investing activities Increase in cash and cash equivalents Cash and cash equivalents, beginning of period (8,805,030) (39,805,310) (1,371,806) (39,805,310) (39,805,310) (1,371,806) (2,600,000) (5,145,126) (1,173,320) (1,173,320) (1,173,320)			
Contributions for capital assets Net cash used in capital and related financing activities Investing activities Investment income Investment received on note receivable Payment received on note receivable Net cash transferred to assets limited as to use Net cash used in investing activities Increase in cash and cash equivalents Cash and cash equivalents, beginning of period 893,352 (39,805,310) 1,371,806 2,600,000 (5,145,126) (1,173,320) 192,318,150 192,318,150	_		
Net cash used in capital and related financing activities Investing activities Investment income Investment received on note receivable Payment received on note receivable Net cash transferred to assets limited as to use Net cash used in investing activities Increase in cash and cash equivalents Cash and cash equivalents, beginning of period (39,805,310) (39,805,310) (39,805,310) (1,371,806) (2,600,000) (5,145,126) (1,173,320) (1,173,320) (1,173,320)			
Investing activities Investment income 1,371,806 Payment received on note receivable 2,600,000 Net cash transferred to assets limited as to use (5,145,126) Net cash used in investing activities (1,173,320) Increase in cash and cash equivalents 192,318,150 Cash and cash equivalents, beginning of period 113,584,247	·		
Investment income 1,371,806 Payment received on note receivable 2,600,000 Net cash transferred to assets limited as to use (5,145,126) Net cash used in investing activities (1,173,320) Increase in cash and cash equivalents 192,318,150 Cash and cash equivalents, beginning of period 113,584,247	Net cash used in capital and related financing activities	_	(39,805,310)
Investment income 1,371,806 Payment received on note receivable 2,600,000 Net cash transferred to assets limited as to use (5,145,126) Net cash used in investing activities (1,173,320) Increase in cash and cash equivalents 192,318,150 Cash and cash equivalents, beginning of period 113,584,247	Investing activities		
Payment received on note receivable 2,600,000 Net cash transferred to assets limited as to use (5,145,126) Net cash used in investing activities (1,173,320) Increase in cash and cash equivalents 192,318,150 Cash and cash equivalents, beginning of period 113,584,247	-		1,371,806
Net cash transferred to assets limited as to use Net cash used in investing activities(5,145,126) (1,173,320)Increase in cash and cash equivalents192,318,150Cash and cash equivalents, beginning of period113,584,247	Payment received on note receivable		
Net cash used in investing activities(1,173,320)Increase in cash and cash equivalents192,318,150Cash and cash equivalents, beginning of period113,584,247	•		
Cash and cash equivalents, beginning of period 113,584,247	Net cash used in investing activities	_	
	Increase in cash and cash equivalents	_	192,318,150
Cash and cash equivalents, end of period \$ 305,902,397	Cash and cash equivalents, beginning of period		113,584,247
	Cash and cash equivalents, end of period	\$_	305,902,397


ERLANGER HEALTH SYSTEM CONSOLIDATED STATISTICAL VOLUMES FOR THE PERIOD ENDING JULY 2019 TO JUNE 2020


		YTD TI	HROUGH 06/3	30/2020 PRIOR	
	ACTUAL	BUDGET	VARIANCE	YEAR	CHANGE
<u>CENSUS</u>					
LICENSED BEDS	848	859	-1.3%	848	0.0%
BEDS IN SERVICE	696	698		698	-0.3%
AVERAGE DAILY CENSUS	516	551	-6.4%	546	-5.4%
OCCUPANCY PERCENTAGE	74.13%	78.96%	-6.1%	78.16%	-5.2%
ADMISSIONS					
BEH	25,738	29,920	-14.0%	28,027	-8.2%
TCT	3,216	3,590	-10.4%	3,545	-9.3%
EE	7,999	8,877	-9.9%	8,434	-5.2%
EN	401	530		523	-23.3%
EN SENIOR'S PROGRAM	0 27 25 4	42.047		25	-100.0%
TOTAL	37,354	42,917	-13.0%	40,554	-7.9%
CASE MIX INDEX					
TOTAL PATIENT	1.68	1.64	2.6%	1.65	2.0%
TOTAL PATIENT EXCL NORMAL NEWBORN	1.81	1.77	2.5%	1.77	2.5%
TOTAL MEDICARE PATIENTS	1.92	1.90	1.1%	1.89	1.6%
BEH	1.96	1.92		1.94	1.0%
TCT EXCL NORMAL NEWBORN	2.07			1.89	9.4%
EE	0.98	0.96	2.5%	0.96	2.5%
PATIENT DAYS					
BEH	92,328	100,837	-8.4%	97,822	-5.6%
BEH ICU'S	37,760	40,385	-6.5%	40,934	-7.8%
TCT	7,414	8,224	-9.8%	8,159	-9.1%
TCT PICU	2,710	2,578	5.1%	2,739	-1.1%
TCT NICU	19,418			18,839	3.1%
EE	21,860			23,260	-6.0%
EE NICU	1,574			1,542	2.1%
EN EN SENIOR'S PROGRAM	5,771 0	5,212		5,353	7.8%
TOTAL	188,835	201,717		469 199,117	-100.0% -5.2%
101/12	100,000	201,717	0.170	100,117	0.270
AVERAGE LOS					
TOTAL	5.06			4.90	3.1%
MEDICARE	5.13			5.10	0.6%
CASE MIX ADJUSTED BEH	3.00 5.05	2.87 4.72		2.97 4.95	1.1% 2.1%
TCT	9.19			8.39	9.5%
EE	2.73	2.63		2.76	-0.9%
SENIOR'S PROGRAM	0.00	0.00	0.0%	18.76	-100.0%
OBSERVATION DAYS	F 000	F 000	40.50/	E 040	40.00/
BEH TCT	5,982 1,471			5,016	19.3% -10.0%
EE	1,696	1,774 1,352		1,634 1,393	21.8%
EN	80	52		61	30.2%
TOTAL	9,229	8,447	9.3%	8,104	13.9%
UTILIZATION					
MEDICARE MOT	20.2%	22.2%		21.9%	-7.8%
MEDICARE MGT	12.8%	11.8%		12.2%	4.9%
MEDICAID/TENNCARE COMMERCIAL PAY	20.2% 37.2%	21.0% 36.2%		20.6% 36.2%	-1.9% 2.8%
INDIGENT/SELF-PAY	7.7%			7.1%	8.5%
OTHER	1.9%	2.0%		2.0%	-5.0%
	- / -	- , •			
DISCHARGES BY FINANCIAL CLASS					_
MEDICARE	8,167			9,641	-15.3%
MEDICARE MGT	5,893			6,226	-5.3%
MEDICAID/TENNCARE	8,380			8,748	-4.2%
COMMERCIAL PAY INDIGENT/SELF PAY	11,722 3 165			12,313	-4.8% 6.1%
OTHER	3,165 657			2,984 660	-0.5%
TOTAL	37,984	42,918		40,572	-0.5% -6.4%
	,001	,0.0	,0	,	-1170

ERLANGER HEALTH SYSTEM CONSOLIDATED STATISTICAL VOLUMES FOR THE PERIOD ENDING JULY 2019 TO JUNE 2020

National			YTD TI	HROUGH 06/3	30/2020	
SURGICAL INPATIENTS		A O.T. I A I			PRIOR	OLIANOE
Peter		ACTUAL	BUDGET	VARIANCE	YEAR	CHANGE
1,522	SURGICAL INPATIENTS					
TOTAL SURGICAL HOURS B40 946 -1.1.2 978 -1.0.4 TOTAL SURGICAL HOURS B40 303 -1.0.5 1.0.2 TOTAL SURGICAL HOURS B40 -1.0.2 1.0.2 TOTAL SUR		7,750	8,739	-11.3%	8,353	-7.2%
TOTAL SURGICAL PATIENTS						
MEC						
E						
PLAZA SURGERY 5.8 5.0 3.6 % 1.2 3.3 1 % 1.6						
SEH						
SEH						
OSC 1,458 1,317 0,7% 1,324 10,1% CV OR 60 76 -21,1% 59 1,7% TCT 5,991 1,006 -21,1% 6,432 13,1% MEC 1,212 1,075 12,7% 1,086 11,6% EE 6,407 6,681 4,1% 6,449 -0,00 PLAZA SURGERY 3,082 4,000 -23,0% 3,926 -21,5% TOTAL SURGICAL OUTPATIENTS 23,529 25,158 -6.1% 24,756 -4.6% ORTHOSEDIC INPATIENT SURGERIES 3,713 4,272 -13,1% 4,033 -7.7% NEUROSURGERY INPATIENT SURGERIES 3,713 4,272 -13,1% 4,033 -7.4% NEUROSURGERY INPATIENT SURGERIES 3,713 4,272 -13,1% 4,023 -7.7% IPHEART/THORACIC SURGERIES WITH CABS/VALVES 840 946 -11,2% 937 -10,4% DAIVINICIPROCEDURES 1,32 1,32 -1,5% 3,052 -17,2%		5.040	5.040	0.70/	F 400	0.00/
CV OR						
TCT						
MEC						
EE						
Name						
TOTAL SURGICAL PATIENTS 35,263 38,442 -8.3% 37,424 -5.8% TOTAL SURGICAL HOURS 63,534 70,480 -9.9% 67,869 -6.4% ORTHOPEDIC INPATIENT SURGERIES NEUROSURGERY INPATIENT SURGERIES 1,464 1,641 -10.8% 1,565 6.5% IP HEARTITHORACIC SURGERIES WITH CABS/VALVES BARIATRICS PROCEDURES 3,713 1,305 1,2% 1,244 6.2% DAVINCI PROCEDURES 3,77 3,388 -2.8% 378 0.3% CARDIAC CATH LAB PATIENTS 2,527 2,732 -7.5% 3,052 -17.2% EE CARDIAC CATH LAB PATIENTS 667 832 -19.8% 826 -19.2% SURGERY VIP HRS/PROCEDURE 1,38 1,35 2.4% 1,38 0.3% EIRTHS EH LAD (BIRTHS) 2,665 2,863 -7.4% 2,812 -5.8% EE (BIRTHS) 2,946 2,867 11.7% 2,669 10.4% TOTAL 5,596 5,500 1.7% 5,481 2.1% PHYSICIAN PRACTICE OUTPATIENT VISITS 610,032 659,884 -7.6% 584,777 4.3% EE (BIRTHS) HELICOPTER (PATS) HELICOPTER CHERTORE 444 451 2,9% 5,515 9.9% TOTAL 5,596 5,500 1.7% 5,481 2.1% EE (BIRTHS) 5,596 5,500 1.7% 5,481 2.1% EE (BIRTHS) 5,596 5,500 1.7% 5,481 2.1% EE (BIRTHS) 610,032 659,884 -7.6% 584,777 4.3% EE (BIRTHS) EH LICOPTER (PATS) HELICOPTER (PATS) TOTAL 5,596 5,500 1.7% 5,481 2.1% EE (BIRTHS) 610,032 659,884 -7.6% 584,777 4.3% EE (BIRTHS) 610,032 659,884 -7.6%	PLAZA SURGERY			-23.0%		-21.5%
Name	TOTAL SURGICAL OUTPATIENTS	23,629	25,158	-6.1%	24,756	-4.6%
Name						
ORTHOPEDIC INPATIENT SURGERIES NEUROSURGERY INPATIENT SURGERIES NEUROSURGERY INPATIENT SURGERIES 1,464 1,641 -10.8% 1,565 6.5% 6.5% 19 HEART/THORACIC SURGERIES WITH CABS/VALVES BARIATRICS PROCEDURES 1,321 1,305 1.2% 1,244 6.2% BARIATRICS PROCEDURES 3,77 388 -2.8% 3,78 -0.3% CARDIAC CATH LAB PATIENTS 2,527 2,732 -7.5% 3,052 -17.2% EE CARDIAC CATH LAB PATIENTS 667 832 -19.8% 826 -19.2% SURGERY I/P HRS/PROCEDURE SURGERY I/P HRS/PROCEDURE 2,65 2.75 -3.5% 2.72 -2.4% 1.38 0.3% 1.35 2.4% 1.38 0.3%	TOTAL SURGICAL PATIENTS	35,263	38,442	-8.3%	37,424	-5.8%
ORTHOPEDIC INPATIENT SURGERIES NEUROSURGERY INPATIENT SURGERIES NEUROSURGERY INPATIENT SURGERIES 1,464 1,641 -10.8% 1,565 6.5% 6.5% 19 HEART/THORACIC SURGERIES WITH CABS/VALVES BARIATRICS PROCEDURES 1,321 1,305 1.2% 1,244 6.2% BARIATRICS PROCEDURES 3,77 388 -2.8% 3,78 -0.3% CARDIAC CATH LAB PATIENTS 2,527 2,732 -7.5% 3,052 -17.2% EE CARDIAC CATH LAB PATIENTS 667 832 -19.8% 826 -19.2% SURGERY I/P HRS/PROCEDURE SURGERY I/P HRS/PROCEDURE 2,65 2.75 -3.5% 2.72 -2.4% 1.38 0.3% 1.35 2.4% 1.38 0.3%						
ORTHOPEDIC INPATIENT SURGERIES NEUROSURGERY INPATIENT SURGERIES NEUROSURGERY INPATIENT SURGERIES 1,464 1,641 -10.8% 1,565 6.5% 6.5% 19 HEART/THORACIC SURGERIES WITH CABS/VALVES BARIATRICS PROCEDURES 1,321 1,305 1.2% 1,244 6.2% BARIATRICS PROCEDURES 3,77 388 -2.8% 3,78 -0.3% CARDIAC CATH LAB PATIENTS 2,527 2,732 -7.5% 3,052 -17.2% EE CARDIAC CATH LAB PATIENTS 667 832 -19.8% 826 -19.2% SURGERY I/P HRS/PROCEDURE SURGERY I/P HRS/PROCEDURE 2,65 2.75 -3.5% 2.72 -2.4% 1.38 0.3% 1.35 2.4% 1.38 0.3%	TOTAL SURGICAL HOURS	63 534	70 480	-9 9%	67 869	-6.4%
NEUROSURGERY INPATIENT SURGERIES 1,464 1,641 -10.8% 1,565 -6.5% IP HEART/THORACIC SURGERIES WITH CABS/VALVES 840 946 -11.2% 937 -10.4% DAVINCI PROCEDURES 1,321 1,305 1.2% 1,244 6.2% BARIATRICS PROCEDURES 377 388 -2.8% 378 -0.3% CARDIAC CATH LAB PATIENTS 2,527 2,732 -7.5% 3,052 -17.2% EE CARDIAC CATH LAB PATIENTS 667 832 -19.8% 826 -19.2%	TOTAL GONGIOAL TIGGING	00,004	70,400	3.370	07,000	0.470
NEUROSURGERY INPATIENT SURGERIES 1,464 1,641 -10.8% 1,565 -6.5% IP HEART/THORACIC SURGERIES WITH CABS/VALVES 840 946 -11.2% 937 -10.4% DAVINCI PROCEDURES 1,321 1,305 1.2% 1,244 6.2% BARIATRICS PROCEDURES 377 388 -2.8% 378 -0.3% CARDIAC CATH LAB PATIENTS 2,527 2,732 -7.5% 3,052 -17.2% EE CARDIAC CATH LAB PATIENTS 667 832 -19.8% 826 -19.2%	ORTHOPEDIC INPATIENT SURGERIES	3 713	4 272	-13 1%	4 023	-7 7%
PHEART/THORACIC SURGERIES WITH CABS/VALVES 840 946 -11.2% 937 -10.4% DAVINCI PROCEDURES 1,321 1,305 1.2% 1,244 6.2% BARIATRICS PROCEDURES 377 388 2.8% 378 -0.3% CARDIAC CATH LAB PATIENTS 2,527 2,732 -7.5% 3,052 -17.2% EE CARDIAC CATH LAB PATIENTS 667 832 -19.8% 826 -19.2% SURGERY I/P HRS/PROCEDURE 2.65 2.75 -3.5% 2.72 -2.4% SURGERY I/P HRS/PROCEDURE 1.38 1.35 2.4% 1.38 0.3% 1.35 2.4% 1.38 0.3% SURGERY I/P HRS/PROCEDURE 1.38 1.35 1						
DAVINCI PROCEDURES 1,321 1,305 1,2% 1,244 6.2% BARIATRICS PROCEDURES 377 388 -2.8% 378 -0.3% CARDIAC CATH LAB PATIENTS 2,527 2,732 -7.5% 3,052 -17.2% EE CARDIAC CATH LAB PATIENTS 667 832 -19.8% 826 -19.2%						
CARDIAC CATH LAB PATIENTS 2,527 2,732 -7.5% 3,052 -17.2% EE CARDIAC CATH LAB PATIENTS 667 832 -19.8% 826 -19.2% SURGERY I/P HRS/PROCEDURE 2.65 2.75 -3.5% 2.72 -2.4% SURGERY O/P HRS/PROCEDURE 1.38 1.35 2.4% 1.38 0.3% BIRTHS 8BH L&D (BIRTHS) 2.650 2.863 -7.4% 2.812 -5.8% EE (BIRTHS) 2.946 2.637 11.7% 2.669 10.4% TOTAL 5.596 5.500 1.7% 5.481 2.1% PHYSICIAN PRACTICE OUTPATIENT VISITS 610.032 659.884 -7.6% 584,777 4.3% HELICOPTER (PATS) 1.791 1,953 -8.3% 1,842 -2.8% HELICOPTER-LIFEFORCE 1,791 1,953 -8.3% 1,842 -2.8% HELICOPTER-OTHER VENDORS 464 451 2.9% 515 -9.9% TOTAL 30.903 36,564 -10.0% 54,864	DAVINCI PROCEDURES	1,321	1,305	1.2%	1,244	6.2%
EE CARDIAC CATH LAB PATIENTS 667 832 -19.8% 826 -19.2% SURGERY I/P HRS/PROCEDURE 2.65 2.75 -3.5% 2.72 -2.4% SURGERY O/P HRS/PROCEDURE 1.38 1.35 2.4% 1.38 0.3% BIRTHS BEH L&D (BIRTHS) 2,650 2,863 -7.4% 2,812 -5.8% EE (BIRTHS) 2,946 2,637 11.7% 2,669 10.4% TOTAL 5,596 5,500 1.7% 5,481 2.1% PHYSICIAN PRACTICE OUTPATIENT VISITS 610,032 659,884 -7.6% 584,777 4.3% HELICOPTER (PATS) HELICOPTER-LIFEFORCE 1,791 1,953 -8.3% 1,842 -2.8% HELICOPTER-OTHER VENDORS 464 451 2.9% 515 -9.9% TOTAL 32,913 38,632 -14.8% 39,099 -15.8% EE 39,701 41,544 -4.4% 41,162 -3.5% EN 12,202 13,3	BARIATRICS PROCEDURES	377	388	-2.8%	378	-0.3%
SURGERY I/P HRS/PROCEDURE 2.65 2.75 -3.5% 2.72 -2.4% SURGERY O/P HRS/PROCEDURE 1.38 1.35 2.4% 1.38 0.3% BIRTHS BEH L&D (BIRTHS) 2,650 2,863 -7.4% 2,812 -5.8% EE (BIRTHS) 2,946 2,637 11.7% 2,669 10.4% TOTAL 5,596 5,500 1.7% 5,481 2.1% PHYSICIAN PRACTICE OUTPATIENT VISITS 610,032 659,884 -7.6% 584,777 4.3% HELICOPTER (PATS) HELICOPTER (PATS) 3 -8.3% 1,842 -2.8% HELICOPTER-OTHER VENDORS 464 451 2.9% 515 -9.9% TOTAL 32,255 2,404 -6.2% 2,357 -4.3% EMERGENCY ROOM VISITS BEH 50,935 56,564 -10.0% 54,864 -7.2% EC 39,701 41,544 -4.4% 41,162 -3.5% ER 39,701 41,544 -4.4	CARDIAC CATH LAB PATIENTS	2,527	2,732	-7.5%	3,052	-17.2%
SURGERY O/P HRS/PROCEDURE	EE CARDIAC CATH LAB PATIENTS	667	832	-19.8%	826	-19.2%
SURGERY O/P HRS/PROCEDURE						
BIRTHS BEH L&D (BIRTHS) 2,650 2,863 -7.4% 2,812 -5.8% EE (BIRTHS) 2,946 2,637 11.7% 2,669 10.4% TOTAL 5,596 5,500 1.7% 5,481 2.1% PHYSICIAN PRACTICE OUTPATIENT VISITS 610,032 659,884 -7.6% 584,777 4.3% HELICOPTER (PATS) HELICOPTER-LIFEFORCE 1,791 1,953 -8.3% 1,842 -2.8% HELICOPTER-OTHER VENDORS 464 451 2.9% 515 -9.9% TOTAL 2,255 2,404 -6.2% 2,357 -4.3% EMERGENCY ROOM VISITS BEH 50,935 56,564 -10.0% 54,864 -7.2% TOT 32,913 38,632 -14.8% 39,099 -15.8% EE 39,701 41,544 -4.4% 41,162 -3.5% EN 12,202 13,347 -8.6% 13,200 -7.6% TOTAL	SURGERY I/P HRS/PROCEDURE	2.65	2.75	-3.5%	2.72	-2.4%
BIRTHS BEH L&D (BIRTHS) 2,650 2,863 -7.4% 2,812 -5.8% EE (BIRTHS) 2,946 2,637 11.7% 2,669 10.4% TOTAL 5,596 5,500 1.7% 5,481 2.1% PHYSICIAN PRACTICE OUTPATIENT VISITS 610,032 659,884 -7.6% 584,777 4.3% HELICOPTER (PATS) HELICOPTER-LIFEFORCE 1,791 1,953 -8.3% 1,842 -2.8% HELICOPTER-OTHER VENDORS 464 451 2.9% 515 -9.9% TOTAL 2,255 2,404 -6.2% 2,357 -4.3% EMERGENCY ROOM VISITS BEH 50,935 56,564 -10.0% 54,864 -7.2% TOT 32,913 38,632 -14.8% 39,099 -15.8% EE 39,701 41,544 -4.4% 41,162 -3.5% EN 12,202 13,347 -8.6% 13,200 -7.6% TOTAL	SUBCERV O/R HRS/RROCERURE	1 20	1 25	2 40/	1 20	0.3%
BEH L&D (BIRTHS) 2,650 2,863 -7.4% 2,812 -5.8% EE (BIRTHS) 2,946 2,637 11.7% 2,669 10.4% TOTAL 5,596 5,500 1.7% 5,481 2.1% HELICOPTER (PATS) HELICOPTER-LIFEFORCE 1,791 1,953 -8.3% 1,842 -2.8% HELICOPTER-OTHER VENDORS 464 451 2.9% 515 -9.9% TOTAL 2,255 2,404 -6.2% 2,357 -4.3% EMERGENCY ROOM VISITS 5 56,564 -10.0% 54,864 -7.2% TCT 32,913 38,632 -14.8% 39,099 -15.8% EE 39,701 41,544 -4.4% 41,162 -3.5% EN 12,202 13,347 -8.6% 13,200 -7.6% TOTAL 135,751 150,087 -9.6% 148,325 -8.5% EMERGENCY ROOM ADMITS 5 15,409 21,211 -27.4% 18,920 -18.6% <	SONGERT OF THOSE ROOLDONE	1.50	1.55	2.470	1.50	0.576
BEH L&D (BIRTHS) 2,650 2,863 -7.4% 2,812 -5.8% EE (BIRTHS) 2,946 2,637 11.7% 2,669 10.4% TOTAL 5,596 5,500 1.7% 5,481 2.1% HELICOPTER (PATS) HELICOPTER-LIFEFORCE 1,791 1,953 -8.3% 1,842 -2.8% HELICOPTER-OTHER VENDORS 464 451 2.9% 515 -9.9% TOTAL 2,255 2,404 -6.2% 2,357 -4.3% EMERGENCY ROOM VISITS 5 56,564 -10.0% 54,864 -7.2% TCT 32,913 38,632 -14.8% 39,099 -15.8% EE 39,701 41,544 -4.4% 41,162 -3.5% EN 12,202 13,347 -8.6% 13,200 -7.6% TOTAL 135,751 150,087 -9.6% 148,325 -8.5% EMERGENCY ROOM ADMITS 5 15,409 21,211 -27.4% 18,920 -18.6% <	BIRTHS					
PHYSICIAN PRACTICE OUTPATIENT VISITS 10,032 659,884 -7.6% 5,481 2.1%		2.650	2.863	-7.4%	2.812	-5.8%
TOTAL 5,596 5,500 1.7% 5,481 2.1%	,					
HELICOPTER (PATS) HELICOPTER-LIFEFORCE	,					
HELICOPTER (PATS) HELICOPTER-LIFEFORCE						
HELICOPTER-LIFEFORCE	PHYSICIAN PRACTICE OUTPATIENT VISITS	610,032	659,884	-7.6%	584,777	4.3%
HELICOPTER-LIFEFORCE						
HELICOPTER-OTHER VENDORS 464 451 2.9% 515 -9.9% 107AL 2.255 2,404 -6.2% 2,357 -4.3% 2.255 2,404 -6.2% 2,357 -4.3% 2.255 2,404 -6.2% 2,357 -4.3% 2.255 2,404 -6.2% 2,357 -4.3% 2.255 2,404 -6.2% 2,357 -4.3% 2.255 2,404 -6.2% 2,357 -4.3% 2.255 2,404 -6.2% 2,357 -4.3% 2.255 2,404 -6.2% 2,357 -2.28% 2.255 2,404 -6.2% 2.255 2,404 -6.2% 2.255 2,404 -6.2% 2.255 2,404 -6.2% 2.255 2,404 -6.2% 2.255 2,404 -6.2% 2.255 2,404 -6.2% 2.255 2,404 -6.2% 2.255 2,404 -6.2% 2.255 2,404 -6.2% 2.255 2,404 -6.2% 2.255 2,404 -6.2% 2.255 2.2						
TOTAL 2,255 2,404 -6.2% 2,357 -4.3% EMERGENCY ROOM VISITS BEH 50,935 56,564 -10.0% 54,864 -7.2% TCT 32,913 38,632 -14.8% 39,099 -15.8% EE 39,701 41,544 -4.4% 41,162 -3.5% EN 12,202 13,347 -8.6% 13,200 -7.6% TOTAL 135,751 150,087 -9.6% 148,325 -8.5% EMERGENCY ROOM ADMITS 5 5 5 7 -36.0% 3,005 -33.8% EE 1,989 3,107 -36.0% 3,005 -33.8% EE 4,369 5,608 -22.1% 5,516 -20.8% EN 442 602 -26.6% 577 -23.4%					,	
EMERGENCY ROOM VISITS BEH 50,935 56,564 -10.0% 54,864 -7.2% TCT 32,913 38,632 -14.8% 39,099 -15.8% EE 39,701 41,544 -4.4% 41,162 -3.5% EN 12,202 13,347 -8.6% 13,200 -7.6% TOTAL 135,751 150,087 -9.6% 148,325 -8.5% EMERGENCY ROOM ADMITS BEH 15,409 21,211 -27.4% 18,920 -18.6% TCT 1,989 3,107 -36.0% 3,005 -33.8% EE 4,369 5,608 -22.1% 5,516 -20.8% EN 442 602 -26.6% 577 -23.4%						
BEH 50,935 56,564 -10.0% 54,864 -7.2% TCT 32,913 38,632 -14.8% 39,099 -15.8% EE 39,701 41,544 -4.4% 41,162 -3.5% EN 12,202 13,347 -8.6% 13,200 -7.6% TOTAL 135,751 150,087 -9.6% 148,325 -8.5% EMERGENCY ROOM ADMITS BEH 15,409 21,211 -27.4% 18,920 -18.6% TCT 1,989 3,107 -36.0% 3,005 -33.8% EE 4,369 5,608 -22.1% 5,516 -20.8% EN 442 602 -26.6% 577 -23.4%	TOTAL	2,233	2,404	-0.276	2,337	-4.3%
TCT 32,913 38,632 -14.8% 39,099 -15.8% EE 39,701 41,544 -4.4% 41,162 -3.5% EN 12,202 13,347 -8.6% 13,200 -7.6% TOTAL 135,751 150,087 -9.6% 148,325 -8.5% BEH 15,409 21,211 -27.4% 18,920 -18.6% TCT 1,989 3,107 -36.0% 3,005 -33.8% EE 4,369 5,608 -22.1% 5,516 -20.8% EN 442 602 -26.6% 577 -23.4%	EMERGENCY ROOM VISITS					
EE 39,701 41,544 -4.4% 41,162 -3.5% EN 12,202 13,347 -8.6% 13,200 -7.6% TOTAL 135,751 150,087 -9.6% 148,325 -8.5% EMERGENCY ROOM ADMITS BEH 15,409 21,211 -27.4% 18,920 -18.6% TCT 1,989 3,107 -36.0% 3,005 -33.8% EE 4,369 5,608 -22.1% 5,516 -20.8% EN 442 602 -26.6% 577 -23.4%	BEH	50,935	56,564	-10.0%	54,864	-7.2%
EN TOTAL 12,202 13,347 -8.6% 13,200 -7.6% EMERGENCY ROOM ADMITS BEH 15,409 21,211 -27.4% 18,920 -18.6% TCT 1,989 3,107 -36.0% 3,005 -33.8% EE 4,369 5,608 -22.1% 5,516 -20.8% EN 442 602 -26.6% 577 -23.4%	TCT	32,913	38,632	-14.8%	39,099	-15.8%
EMERGENCY ROOM ADMITS 15,409 21,211 -27.4% 18,920 -18.6% TCT 1,989 3,107 -36.0% 3,005 -33.8% EE 4,369 5,608 -22.1% 5,516 -20.8% EN 442 602 -26.6% 577 -23.4%	EE	39,701	41,544	-4.4%	41,162	
EMERGENCY ROOM ADMITS BEH 15,409 21,211 -27.4% 18,920 -18.6% TCT 1,989 3,107 -36.0% 3,005 -33.8% EE 4,369 5,608 -22.1% 5,516 -20.8% EN 442 602 -26.6% 577 -23.4%						
BEH 15,409 21,211 -27.4% 18,920 -18.6% TCT 1,989 3,107 -36.0% 3,005 -33.8% EE 4,369 5,608 -22.1% 5,516 -20.8% EN 442 602 -26.6% 577 -23.4%	IUIAL	135,751	150,087	-9.6%	148,325	-8.5%
BEH 15,409 21,211 -27.4% 18,920 -18.6% TCT 1,989 3,107 -36.0% 3,005 -33.8% EE 4,369 5,608 -22.1% 5,516 -20.8% EN 442 602 -26.6% 577 -23.4%	EMERGENCY ROOM ADMITS					
TCT 1,989 3,107 -36.0% 3,005 -33.8% EE 4,369 5,608 -22.1% 5,516 -20.8% EN 442 602 -26.6% 577 -23.4%	<u> </u>	15,409	21,211	-27.4%	18,920	-18.6%
EE 4,369 5,608 -22.1% 5,516 -20.8% EN 442 602 -26.6% 577 -23.4%						
	EE	4,369	5,608	-22.1%	5,516	-20.8%
TOTAL 22,209 30,528 -27.3% 28,018 -20.7%			602		577	
	TOTAL	22,209	30,528	-27.3%	28,018	-20.7%








ERLANGER HEALTH SYSTEM ERLANGER BLEDSOE CONSOLIDATED STATISTICAL VOLUMES FOR THE PERIOD JULY 2019 TO JUNE 2020


		YTD TH	ROUGH 06/	30/2020	
				PRIOR	
OFNIOLIO	ACTUAL	BUDGET	CHANGE	YEAR	CHANGE
CENSUS	05	0.5	0.00/	0.5	0.00/
LICENSED BEDS	25	25	0.0%	25	0.0%
BEDS IN SERVICE	25	25	0.0%	25	0.0%
AVERAGE DAILY CENSUS	4.83	5.78	-16.5%	5.61	-13.8%
OCCUPANCY PERCENTAGE	19.3%	23.1%	-16.5%	22.4%	-13.8%
ADMISSIONS					
ROUTINE CARE	119	132	-9.8%	145	-17.9%
SWING BED UNIT	77	110	-30.0%	109	-29.4%
TOTAL	196	242	-19.0%	254	-22.8%
CASE MIX INDEX					
MEDICARE	0.91	1.03	-11.2%	1.02	-10.3%
TOTAL PATIENT	0.92	1.02	-10.2%	1.00	-8.4%
PATIENT DAYS					
ROUTINE CARE	388	483	-19.7%	489	-20.7%
SWING BED UNIT	1,380	1,634	-15.5%	1,557	-11.4%
TOTAL	1,768	2,117	-16.5%	2,046	-13.6%
AVERAGE LOG					
AVERAGE LOS		0.75	0.40/		40.007
TOTAL	9.02	8.75	3.1%	8.06	12.0%
ROUTINE CARE	3.26	3.66	-10.9%	3.37	-3.3%
SWING BED UNIT	17.92	14.85	20.6%	14.28	25.5%
OBSERVATION DAYS					
ROUTINE CARE	176	182	-3.1%	177	-0.2%
NOOTINE CARE	170	102	-3.170	177	-0.2 /6
GROSS REVENUE BY PAYER					
MEDICARE	24.4%	26.5%	-7.9%	25.9%	-5.8%
MEDICARE MGT	18.6%	15.6%	19.2%	16.6%	12.0%
MEDICAID/TENNCARE	22.4%	22.7%	-1.3%	22.4%	0.0%
COMMERCIAL PAY	22.7%	22.2%	2.3%	22.4%	1.3%
INDIGENT/SELF-PAY	10.3%	11.4%	-9.6%	11.0%	-6.4%
OTHER	1.5%	1.7%	-11.8%	1.6%	-6.3%
DISCULARCES BY DAYER					
DISCHARGES BY PAYER	106	150	17 /0/	160	OF 40/
MEDICARE MOT	126	152	-17.4%	169	-25.4%
MEDICARE MGT	43	20	116.2%	56	-23.2%
MEDICAID/TENNCARE	9	33	-72.9%	10	-10.0%
COMMERCIAL PAY	10	18	-43.4%	11	-9.1%
INDIGENT/SELF-PAY	6	19	-68.1%	5	20.0%
OTHER	104	1	-100.0%	7	-100.0%
TOTAL	194	243	-20.1%	258	-24.8%
EMERGENCY ROOM VISITS					
Bledsoe	4,817	4,946	-2.6%	4,916	-2.0%
Sequatchie Valley		10,541	-2.6% -10.5%	10,592	
TOTAL	9,436	15,487	-8.0%	15,508	-10.9% -8.1%
IOIAL	14,203	10,407	-0.0%	13,306	-0.170


ERLANGER HEALTH SYSTEM ERLANGER WESTERN CAROLINA HOSPITAL CONSOLIDATED STATISTICAL VOLUMES FOR THE PERIOD JULY 2019 THRU JUNE 2020


		YTD TH	ROUGH 6/3	0/2020	
		11011		PRIOR	
	ACTUAL	BUDGET	CHANGE	YEAR	CHANGE
CENSUS					
LICENSED BEDS	57	57	0.0%	57	0.0%
BEDS IN SERVICE	25	25	0.0%	25	0.0%
AVERAGE DAILY CENSUS	14	18	-21.9%	17	-18.9%
OCCUPANCY PERCENTAGE	56.0%	71.7%	-21.9%	69.0%	-18.9%
-					
ADMISSIONS					
ROUTINE CARE	1.426	1,799	-20.7%	1,742	-18.1%
SWING BED UNIT	44	1,733	266.7%	17	158.8%
TOTAL	1,470	1,811	-18.8%	1,759	-16.4%
	- 1,110	.,		1,100	
CASE MIX INDEX					
MEDICARE	1.48	1.35	9.7%	1.42	4.6%
TOTAL PATIENT	1.43	1.35	5.8%	1.38	3.7%
TOMETAILENT	1.73	1.00	J.U /0	1.50	5.1 /0
PATIENT DAYS					
ROUTINE CARE	4,577	6,499	-29.6%	6,116	-25.2%
SWING BED UNIT	545	60	808.3%	180	202.8%
TOTAL	5,122	6,559	-21.9%	6,296	-18.6%
		,			
AVERAGE LOS					
TOTAL	3.48	3.62	-3.8%	3.58	-2.7%
ROUTINE CARE	3.21	3.61	-11.2%	3.51	-8.6%
SWING BED UNIT	12.39	5.00	147.7%	10.59	17.0%
	12.00	3.00	70	. 5.55	17.070
OBSERVATION DAYS					
ROUTINE CARE	551	430	28.1%	467	18.0%
NOOTHINE OFFICE	JJ 1	400	20.1/0	407	10.070
GROSS REVENUE BY PAYER					
MEDICARE	40.5%	42.7%	-5.2%	42.2%	-4.0%
MEDICARE MGT	16.8%	13.9%	20.9%	14.2%	18.3%
MEDICAID/TENNCARE	10.0%	12.1%	-17.4%	11.9%	-16.0%
COMMERCIAL PAY	20.0%	20.1%	-0.5%	19.5%	2.6%
INDIGENT/SELF-PAY	11.7%	11.1%	5.4%	11.3%	3.5%
OTHER	1.0%	0.1%	900.0%	0.9%	0.0%
		2,0	3 - 2 - 0 / 0	2.0,0	2.0,0
DISCHARGES BY PAYER					
MEDICARE	693	887	-21.9%	855	-18.9%
MEDICARE MGT	248	283	-12.4%	277	-10.5%
MEDICAID	130	227	-42.7%	220	-40.9%
COMMERCIAL PAY	192	246	-22.0%	229	-16.2%
INDIGENT/SELF-PAY	158	131	20.6%	151	4.6%
OTHER	9	12	-25.0%	8	12.5%
TOTAL	1,430	1,786	-19.9%	1,740	-17.8%
					_
SURGICAL PATIENTS					
INPATIENT	379	560	-32.3%	493	-23.1%
OUTPATIENT	1,940	2,140	-9.3%	2,088	-7.1%
TOTAL	2,319	2,700	-14.1%	2,581	-10.2%
EMERGENCY ROOM VISITS	15,928	18,540	-14.1%	18,459	-13.7%
EMERGENCY ROOM ADMITS	1,195	1,445	-17.3%	1,318	-9.3%
PHYSICIAN PRACTICE OUTPATIENT VISITS	54,741	59,173	-7.5%	51,205	6.9%


Erlanger Health System Ratio Analysis June 30, 2020



















Erlanger Health System Ratio Analysis June 30, 2020














1. Selected Accounting Policies

Organization

Erlanger Health System (the System) was created by a private act passed by the General Assembly of the State of Tennessee on March 11, 1976, and adopted by a majority of the qualified voters of Hamilton County, Tennessee on August 5, 1976. The System owns and or operates Baroness Erlanger Hospital, Children's Hospital at Erlanger, Erlanger East Hospital, Erlanger North Hospital (collectively "Erlanger Medical Center"), Erlanger Bledsoe Hospital, Erlanger Western Carolina Hospital, Erlanger Community Health Centers, ContinuCare Health Services, Inc., and Erlanger Health Plan Trust. The System is considered the primary governmental unit for financial reporting purposes.

Charity Care

The System accepts patients regardless of their ability to pay. A patient is classified as a charity patient by reference to certain policies established by the County Auditor with regard to the Hamilton County indigent program or by the System for other patients of the System. Essentially, these policies define charity services as those services for which no minimal payment is anticipated. In assessing a patient's inability to pay, the System and the County utilize generally recognized poverty income levels, but also include certain cases where incurred charges are significant when compared to income of the patient. These charges are not included in net patient service revenue.

Investments

The System's investments are reported at fair market value based on quoted market prices in accordance with GASB Statement No. 31, *Accounting and Financial Reporting for Certain Investments and for External Investment Pools*. The System invests in governmental and municipal bonds, corporate bonds, equity securities and short-term investments.

Accounting Standards

Pursuant to GASB Statement No. 20, Accounting and Financial Reporting for Proprietary Funds and Other Governmental Entities That Use Proprietary Fund Accounting, the System has elected to apply the provisions of all relevant pronouncements of the Financial Accounting Standards Board (FASB), including those issued after November 30, 1989, that do not conflict with or contradict GASB pronouncements.

2. Net Patient Service Revenue

A reconciliation of the amount of services provided to patients at established rates to net patient service revenue as presented in the statements of revenue and expenses is as follows:

	Year to date June 30, 2020	Year to date June 30, 2019
Inpatient service charges	\$ 1,926,342,968	\$ 1,956,711,873
Outpatient service charges	1,875,039,367	1,849,440,980
Gross patient service charges	3,801,382,335	3,806,152,853
Less: Contractual adjustments and other discounts Hamilton County charity care (net of appropriation of \$1,500,000 in fiscal YTD 2020 and \$1,500,000 in fiscal	2,452,210,084	2,448,378,217
YTD 2019 from Hamilton County)	6,195,293	9,825,126
Bad debt	86,028,853	115,540,435
Other charity care	263,326,683	182,942,831
Contractual adjustments, charity care, and bad debt	2,807,760,913	2,756,686,609
Net patient service revenue	\$ 993,621,422	\$ 1,049,466,244

The Private Act of the State of Tennessee establishing the System obligates the System to make its facilities and patient care programs available to the indigent residents of Hamilton County to the extent of funds appropriated by Hamilton County and adjusted operating profits, as defined. The annual appropriation from Hamilton County is not to be less than \$3,000,000 in each fiscal year without approval of the System, so long as the 1966 Hamilton County Sales Tax Agreement remains in effect. The annual appropriation from the Hamilton County Sales Tax Agreement was \$1.5M for fiscal year 2020 and 2019

For fiscal 2019, Erlanger Medical Center recognized revenue of \$10,018,888 for essential access payment, \$23,249,236 from the Public Hospital Supplemental Payment Pool, \$674,316 from the State of Tennessee for Trauma and \$8,823,579 from the State of Tennessee for disproportionate share.

For fiscal 2020, Erlanger Medical Center recognized revenue of \$12,351,244 for essential access payment, \$23,814,971 from the Public Hospital Supplemental Payment Pool, \$916,390 from the State of Tennessee for Trauma, and \$9,083,971 from the State of Tennessee for disproportionate share.

3. Non-Patient Revenue

The System recognized \$55.9 million of stimulus funds as non-patient revenue in the current year to partially offset lost revenues and increased expenses during the COVID-19 pandemic.

4. Cash and Cash Equivalents

Cash and cash equivalents reported on the balance sheet include cash on hand and deposits with financial institutions including demand deposits and certificates of deposit. Cash and cash equivalents consist of the following:

	June 30,		June 30,
General Fund	2020		2019
Demand deposits	\$ 268,417,482	-	\$ 88,076,384
Cash on hand	23,788		22,668
Temporary investments	 37,461,127	_	25,485,195
Total cash and temporary investments	\$ 305,902,397	_	\$ 113,584,247

Temporary investments include certificates of deposit and repurchase agreements. Demand deposits are insured by the Federal Deposit Insurance Corporation up to \$250,000 per institution. Demand deposits, certificates of deposit and repurchase agreements are collateralized with securities held by a third party in the System's name.

The System received \$93.1 million in Medicare advance payments to hedge against liquidity issues in the near future. Based on current regulations, this money will have to be paid back within the upcoming year. At this point, the System has not had to utilize these funds and has not drawn on the \$64 million lines of credit.

5. Net Property, Plant and Equipment

Net property, plant and equipment consist of the following:

	June 30, 2020	June 30, 2019
Land and Improvements	\$ 25,270,069	\$ 24,194,936
Buildings	300,915,011	302,107,129
Equipment	548,613,048	539,881,568
	874,798,128	866,183,633
Less accumulated depreciation	(581,541,545)	(556,296,331)
	293,256,583	309,887,302
Construction in progress	6,273,641	4,162,662
	\$ 299,530,224	\$ 314,049,964

6. Assets Whose Use is Limited

Assets whose use is limited consist of the following:

	June 30,	June 30,
	2020	2019
Investment Portfolio	\$ 111,302,776	\$ 106,243,398
Self Insurance Trust	7,096,943	3,392,892
HMO Trust	1,719,341	1,674,024
Restricted by others for specific purposes	0	624,960
	120,119,060	111,935,274
Less current portion	(2,222)	(2,283)
	\$ 120,116,838	\$ 111,932,991

Assets whose use is limited by the Board of Trustees for capital improvements consist primarily of United States Government and government agency obligations or other liquid assets, which are to be used for the replacement of property and equipment or for any other purposes so designated.

All funds are collateralized with securities held by the pledging financial institution's trust department or agent in the System's name.

7. Long-term Debt

Long-term debt consists of:

	June 30, 2020	June 30, 2019
\$149,920,000 Hospital Revenue and Refunding Bonds Series 2014, including bond issue premium of \$7,056,246 and \$7,347,225 in 2020 and 2019, respectively	\$ 156,776,246	\$ 157,167,225
	156,776,246	157,167,225
Other (includes 2018A Note of \$22,175,000)	44,106,224	51,514,370
	200,882,470	208,681,595
Less current portion	(13,043,446)	(5,644,324)
	\$ 187,839,024	\$ 203,037,271

8. Pension Plan

The System sponsors a single employer defined benefit pension plan covering substantially all employees meeting certain eligibility requirements. In addition to normal retirement benefits, the plan also provides for early retirement, delayed retirement, disability and death benefits. The System's funding policy is to fund actuarially determined costs, using the projected unit credit method, as they accrue. The System has the right to amend, in whole or in part, any or all of the provisions of the plan. Further information about the plan is contained in the pamphlet, Pension Plan Summary Description, copies of which are available from the Pension Committee. The plan covers all employees hired prior to July 1, 2009. The plan was frozen on June 21, 2014.

In June 2012, the Governmental Accounting Standards Board (GASB) issued Statement No. 68, Accounting and Financial Reporting for Pensions. Statement No. 68 provides guidance for improved accounting and financial reporting by state and local government entities related to pensions. It also replaces the requirements of GASB Statement No. 27 and Statement No. 50, as they relate to pensions that are provided through pension plans administered as trusts or equivalent arrangements that meet certain criteria. Additionally, the GASB issued Statement No. 71, Pension Transition for Contributions Made Subsequent to the Measurement Date, which is effective concurrent with Statement No. 68. Among other requirements, Erlanger Health System recorded a net pension liability that is based on fiduciary plan net position rather than on plan funding. Erlanger Health System adopted these Statements in 2015.

9. Investments in Affiliates

Cyberknife of Chattanooga, LLC

During fiscal year 2011, Cyberknife was capitalized by contributions from the Primary Health System and certain other minority partners. Cyberknife provides radiation therapy services, specifically robotic stereotactic radiosurgical services, through the use of a cyberknife stereotactic radiosurgery system on the Primary Health System campus. The Primary Health System owns 51% of Cyberknife's outstanding membership units.

UT-Erlanger Medical Group, Inc

The Medical Group was formed June 30, 2011 and provides professional healthcare services to the public and related services through its employed and contracted licensed physicians and other supporting healthcare providers. The Medical Group has no members; however, the Primary Health System may access the Medical Group's services. The Primary Health System is not entitled to any potential earnings of the Medical Group except for compensation for services rendered to the Medical Group on its behalf. Currently, the entity is inactive.

ContinuCare Health Services, Inc.

During 2018, ContinuCare sold its home health and medical equipment businesses to a third party. As part of the home health sale, the Primary Health System received a 25% interest in a home health joint venture in exchange for certain intangible rights granted to the third party. This joint venture is accounted for under the equity method of accounting and is not material to the combined financial statements. ContinuCare is expected to continue to operate certain remaining lines of business.

Erlanger Behavioral Health

The Primary Health System is 20% owner of a joint venture to provide behavioral health services in its market area. The joint venture saw its first patients in June 2018.

Erlanger Express Care

In June 2019, the Primary Health System entered into a joint venture with EN, LLC to provide urgent care services in the market area. The System is 20% owner of the joint venture.

10. Medical Malpractice and General Liability Claims

As of January 1, 1976, the System adopted a self-insurance plan to provide for malpractice and general liability claims and expenses arising from services rendered subsequent to that date. In 1980, the System's Self-Insurance Trust Agreement was amended to include all coverages that a general public liability insurance policy would cover. In 1988, the Agreement was amended and restated to comply with amendments to the Tennessee Governmental Tort Liability Act and to formally include any claims and expenses related to acts of employees of the System. In accordance with Medicare and Medicaid regulations, the System is funding the estimated liabilities through an irrevocable trust fund with a bank. The annual deposit to the self-insurance trust fund is determined by management based on known and threatened claims, consultation with legal counsel and a report of an independent casualty actuary. Losses against the System are generally limited by the Tennessee Governmental Tort Liability Act to \$300,000 for injury or death to any one person in any one accident, occurrence or act and \$700,000 in the aggregate. However, claims against health care practitioners are not subject to the foregoing limits applicable to the System. Any such individuals employed by the System are covered by the Trust to the limits set forth therein.

In the opinion of management, the trust fund assets are adequate at June 30, 2020, to cover potential liability and malpractice claims and expenses, which may have been incurred to that date.

The System provides for claims and expenses in the period in which the incidence related to such claims occur based on historical experience and consultation with legal counsel. It is the opinion of management that the estimated accrued malpractice cost at June 30, 2020 and 2019 is adequate to cover potential liability and malpractice claims, which may have been incurred but not reported to the System. The System is a defendant in certain litigation arising from the normal course of business. The opinion of management and counsel is that losses, if any, that may arise from such litigation will not be material to the financial statements of the System.

11. 403(b) Retirement Plan

The System has a 403(b) and 401(a) matching program. The plans are for the benefit of generally all employees 25 years of age or older with at least 12 months of employment. The System will match 50% of the eligible participant's contribution up to 2% of the employee's earnings. For eligible employees hired on/after July 1, 2009, the System will make contributions equal to 3% of their earnings. Active employees in the frozen pension plan are eligible for this 3% company contribution as of July 6, 2014. These contributions will be invested in the employees' 401(a) plan, regardless if the employee is making contributions. These employees will also have access to the 401(a) matching program. Additionally, active employees in the frozen pension plan that met the Rule of 75 as of the freeze date, received a 2.5% company contribution through fiscal 2019. The match was temporarily suspended on March 30, 2020 for cost containment measures due to the COVID-19 pandemic.